1
|
Josserand V, Lavaud J, Keramidas M, Collet C, Traboulsi W, Hoffmann P, Feige JJ, Benharouga M, Coll JL, Alfaidy N. RGD-Based Fluorescence to Assess Placental Angiogenesis. Methods Mol Biol 2024; 2728:131-136. [PMID: 38019397 DOI: 10.1007/978-1-0716-3495-0_11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2023]
Abstract
Normal fetal growth and placental development depend on active angiogenesis occurring at the fetomaternal interface throughout pregnancy. Nevertheless, reliable in vivo methods to assess placental angiogenesis are still missing. Here, we describe a quantitative and noninvasive in vivo method to specifically measure placental neovascularization in the gravid mouse. This method uses a technique based on the measurement of a fluorescent molecule Angiostamp700 that targets the alpha v beta 3 (αvβ3) integrin, a protein that is highly expressed by endothelial cells during the neovascularization and by trophoblast cells during invasion of the maternal decidua. Due to this noninvasive method, quantification of the fetomaternal angiogenic activity and information regarding the outcome of pregnancy are now possible.
Collapse
Affiliation(s)
- Veronique Josserand
- Institute for Advanced Biosciences, INSERM-UGA U1209, CNRS UMR 5309, La Tronche, France
| | - Jonathan Lavaud
- Institute for Advanced Biosciences, INSERM-UGA U1209, CNRS UMR 5309, La Tronche, France
| | - Michelle Keramidas
- Institute for Advanced Biosciences, INSERM-UGA U1209, CNRS UMR 5309, La Tronche, France
| | - Constance Collet
- Institut National de la Santé et de la Recherche Médicale, Inserm U1292, Biosanté, Grenoble, France
- University Grenoble-Alpes, Grenoble, France
- Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France
| | - Wael Traboulsi
- Laboratory for Immuno-Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| | - Pascale Hoffmann
- Institut National de la Santé et de la Recherche Médicale, Inserm U1292, Biosanté, Grenoble, France
- University Grenoble-Alpes, Grenoble, France
- Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France
- Centre Hospitalo-Universitaire Grenoble Alpes, Service Obstétrique, CS 10217, Grenoble Cedex 9, France
- Université Grenoble Alpes, Grenoble, France
| | - Jean-Jacques Feige
- Institut National de la Santé et de la Recherche Médicale, Inserm U1292, Biosanté, Grenoble, France
- University Grenoble-Alpes, Grenoble, France
- Centre Hospitalo-Universitaire Grenoble Alpes, Service Obstétrique, CS 10217, Grenoble Cedex 9, France
- Université Grenoble Alpes, Grenoble, France
| | - Mohamed Benharouga
- Institut National de la Santé et de la Recherche Médicale, Inserm U1292, Biosanté, Grenoble, France
- University Grenoble-Alpes, Grenoble, France
- Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France
| | - Jean-Luc Coll
- Institute for Advanced Biosciences, INSERM-UGA U1209, CNRS UMR 5309, La Tronche, France
| | - Nadia Alfaidy
- Institut National de la Santé et de la Recherche Médicale, Inserm U1292, Biosanté, Grenoble, France.
- University Grenoble-Alpes, Grenoble, France.
- Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France.
- Centre Hospitalo-Universitaire Grenoble Alpes, Service Obstétrique, CS 10217, Grenoble Cedex 9, France.
- Université Grenoble Alpes, Grenoble, France.
| |
Collapse
|
2
|
Jia T, Jacquet T, Dalonneau F, Coudert P, Vaganay E, Exbrayat-Héritier C, Vollaire J, Josserand V, Ruggiero F, Coll JL, Eymin B. FGF-2 promotes angiogenesis through a SRSF1/SRSF3/SRPK1-dependent axis that controls VEGFR1 splicing in endothelial cells. BMC Biol 2021; 19:173. [PMID: 34433435 PMCID: PMC8390225 DOI: 10.1186/s12915-021-01103-3] [Citation(s) in RCA: 49] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2021] [Accepted: 07/16/2021] [Indexed: 02/07/2023] Open
Abstract
Background Angiogenesis is the process by which new blood vessels arise from pre-existing ones. Fibroblast growth factor-2 (FGF-2), a leading member of the FGF family of heparin-binding growth factors, contributes to normal as well as pathological angiogenesis. Pre-mRNA alternative splicing plays a key role in the regulation of cellular and tissular homeostasis and is highly controlled by splicing factors, including SRSFs. SRSFs belong to the SR protein family and are regulated by serine/threonine kinases such as SRPK1. Up to now, the role of SR proteins and their regulators in the biology of endothelial cells remains elusive, in particular upstream signals that control their expression. Results By combining 2D endothelial cells cultures, 3D collagen sprouting assay, a model of angiogenesis in cellulose sponges in mice and a model of angiogenesis in zebrafish, we collectively show that FGF-2 promotes proliferation, survival, and sprouting of endothelial cells by activating a SRSF1/SRSF3/SRPK1-dependent axis. In vitro, we further demonstrate that this FGF-2-dependent signaling pathway controls VEGFR1 pre-mRNA splicing and leads to the generation of soluble VEGFR1 splice variants, in particular a sVEGFR1-ex12 which retains an alternative last exon, that contribute to FGF-2-mediated angiogenic functions. Finally, we show that sVEGFR1-ex12 mRNA level correlates with that of FGF-2/FGFR1 in squamous lung carcinoma patients and that sVEGFR1-ex12 is a poor prognosis marker in these patients. Conclusions We demonstrate that FGF-2 promotes angiogenesis by activating a SRSF1/SRSF3/SRPK1 network that regulates VEGFR1 alternative splicing in endothelial cells, a process that could also contribute to lung tumor progression. Supplementary Information The online version contains supplementary material available at 10.1186/s12915-021-01103-3.
Collapse
Affiliation(s)
- Tao Jia
- Institute For Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, Site Santé, Allée des Alpes, 38700, La Tronche, France.,Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China
| | - Thibault Jacquet
- Institute For Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, Site Santé, Allée des Alpes, 38700, La Tronche, France
| | - Fabien Dalonneau
- Institute For Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, Site Santé, Allée des Alpes, 38700, La Tronche, France
| | - Pauline Coudert
- Institut de Génomique Fonctionnelle de Lyon, ENS de Lyon, UMR CNRS 5242, Université Lyon 1, 46 Allée d'Italie, 69364, Lyon Cedex 07, France
| | - Elisabeth Vaganay
- Institut de Génomique Fonctionnelle de Lyon, ENS de Lyon, UMR CNRS 5242, Université Lyon 1, 46 Allée d'Italie, 69364, Lyon Cedex 07, France
| | - Chloé Exbrayat-Héritier
- Institut de Génomique Fonctionnelle de Lyon, ENS de Lyon, UMR CNRS 5242, Université Lyon 1, 46 Allée d'Italie, 69364, Lyon Cedex 07, France
| | - Julien Vollaire
- Institute For Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, Site Santé, Allée des Alpes, 38700, La Tronche, France
| | - Véronique Josserand
- Institute For Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, Site Santé, Allée des Alpes, 38700, La Tronche, France
| | - Florence Ruggiero
- Institut de Génomique Fonctionnelle de Lyon, ENS de Lyon, UMR CNRS 5242, Université Lyon 1, 46 Allée d'Italie, 69364, Lyon Cedex 07, France
| | - Jean-Luc Coll
- Institute For Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, Site Santé, Allée des Alpes, 38700, La Tronche, France
| | - Béatrice Eymin
- Institute For Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, Site Santé, Allée des Alpes, 38700, La Tronche, France.
| |
Collapse
|
3
|
Jia T, Vaganay E, Carpentier G, Coudert P, Guzman-Gonzales V, Manuel R, Eymin B, Coll JL, Ruggiero F. A collagen Vα1-derived fragment inhibits FGF-2 induced-angiogenesis by modulating endothelial cells plasticity through its heparin-binding site. Matrix Biol 2020; 94:18-30. [DOI: 10.1016/j.matbio.2020.07.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2020] [Revised: 07/10/2020] [Accepted: 07/10/2020] [Indexed: 01/22/2023]
|
4
|
Duret D, Grassin A, Henry M, Jacquet T, Thoreau F, Denis-Quanquin S, Coll JL, Boturyn D, Favier A, Charreyre MT. “Polymultivalent” Polymer–Peptide Cluster Conjugates for an Enhanced Targeting of Cells Expressing αvβ3 Integrins. Bioconjug Chem 2017; 28:2241-2245. [DOI: 10.1021/acs.bioconjchem.7b00362] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Damien Duret
- Univ Lyon, Université Lyon 1, INSA de
Lyon, CNRS, Laboratoire Ingénierie des Matériaux Polymères,
UMR5223, F-69621 Villeurbanne, France
- Univ Lyon, Ens de Lyon, CNRS, Laboratoire Joliot-Curie,
USR3010, F-69364 Lyon, France
| | - Adrien Grassin
- Université Grenoble Alpes, CNRS, DCM UMR 5250, F-38000 Grenoble, France
| | - Maxime Henry
- Centre
de Recherche UGA-INSERM U1209 - UMR CNRS 5309, Institute for Advanced Biosciences, F-38700 Grenoble, France
| | - Thibault Jacquet
- Centre
de Recherche UGA-INSERM U1209 - UMR CNRS 5309, Institute for Advanced Biosciences, F-38700 Grenoble, France
| | - Fabien Thoreau
- Université Grenoble Alpes, CNRS, DCM UMR 5250, F-38000 Grenoble, France
- Centre
de Recherche UGA-INSERM U1209 - UMR CNRS 5309, Institute for Advanced Biosciences, F-38700 Grenoble, France
| | - Sandrine Denis-Quanquin
- Univ Lyon, Ens de Lyon, CNRS, Université Lyon 1, Laboratoire de Chimie, UMR5182, F-69342 Lyon, France
| | - Jean-Luc Coll
- Centre
de Recherche UGA-INSERM U1209 - UMR CNRS 5309, Institute for Advanced Biosciences, F-38700 Grenoble, France
| | - Didier Boturyn
- Université Grenoble Alpes, CNRS, DCM UMR 5250, F-38000 Grenoble, France
| | - Arnaud Favier
- Univ Lyon, Université Lyon 1, INSA de
Lyon, CNRS, Laboratoire Ingénierie des Matériaux Polymères,
UMR5223, F-69621 Villeurbanne, France
- Univ Lyon, Ens de Lyon, CNRS, Laboratoire Joliot-Curie,
USR3010, F-69364 Lyon, France
| | - Marie-Thérèse Charreyre
- Univ Lyon, Université Lyon 1, INSA de
Lyon, CNRS, Laboratoire Ingénierie des Matériaux Polymères,
UMR5223, F-69621 Villeurbanne, France
- Univ Lyon, Ens de Lyon, CNRS, Laboratoire Joliot-Curie,
USR3010, F-69364 Lyon, France
| |
Collapse
|
5
|
Desroches-Castan A, Quélard D, Demeunynck M, Constant JF, Dong C, Keramidas M, Coll JL, Barette C, Lafanechère L, Feige JJ. A new chemical inhibitor of angiogenesis and tumorigenesis that targets the VEGF signaling pathway upstream of Ras. Oncotarget 2016; 6:5382-411. [PMID: 25742784 PMCID: PMC4467156 DOI: 10.18632/oncotarget.2979] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2014] [Accepted: 12/19/2014] [Indexed: 02/07/2023] Open
Abstract
The efficacy of anti-angiogenic therapies on cancer patients is limited by the emergence of drug resistance, urging the search for second-generation drugs. In this study, we screened an academic chemical library (DCM, University of Grenoble-Alpes) and identified a leader molecule, COB223, that inhibits endothelial cell migration and proliferation. It inhibits also Lewis lung carcinoma (LLC/2) cell proliferation whereas it does not affect fibroblast proliferation. The anti-angiogenic activity of COB223 was confirmed using several in vitro and in vivo assays. In a mouse LLC/2 tumor model, ip administration of doses as low as 4 mg/kg COB223 efficiently reduced the tumor growth rate. We observed that COB223 inhibits endothelial cell ERK1/2 phosphorylation induced by VEGF, FGF-2 or serum and that it acts downstream of PKC and upstream of Ras. This molecule represents a novel anti-angiogenic and anti-tumorigenic agent with an original mechanism of action that deserves further development as an anti-cancer drug.
Collapse
Affiliation(s)
- Agnès Desroches-Castan
- Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1036, Biology of Cancer and Infection, Grenoble, F-38054, France.,Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Commissariat à l'Energie Atomique (CEA), DSV/iRTSV, Grenoble, F-38054, France
| | - Delphine Quélard
- Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1036, Biology of Cancer and Infection, Grenoble, F-38054, France.,Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Commissariat à l'Energie Atomique (CEA), DSV/iRTSV, Grenoble, F-38054, France.,Janssen, Pharmaceutical Companies of Johnson and Johnson, Issy-les-Moulineaux, F-92130, France
| | - Martine Demeunynck
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Centre National de la Recherche Scientifique (CNRS), UMR 5063, Department of Molecular Pharmacochemistry, Grenoble, F-38041, France
| | - Jean-François Constant
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Centre National de la Recherche Scientifique (CNRS), UMR 5250, Department of Molecular Chemistry, Grenoble, F-38041, France
| | - Chongling Dong
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Centre National de la Recherche Scientifique (CNRS), UMR 5250, Department of Molecular Chemistry, Grenoble, F-38041, France
| | - Michelle Keramidas
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 823, Albert Bonniot Research Center, La Tronche, F-38700, France
| | - Jean-Luc Coll
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 823, Albert Bonniot Research Center, La Tronche, F-38700, France
| | - Caroline Barette
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Commissariat à l'Energie Atomique (CEA), DSV/iRTSV, Grenoble, F-38054, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1038, Large Scale Biology, Grenoble, F-38054, France
| | - Laurence Lafanechère
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Commissariat à l'Energie Atomique (CEA), DSV/iRTSV, Grenoble, F-38054, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 823, Albert Bonniot Research Center, La Tronche, F-38700, France
| | - Jean-Jacques Feige
- Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1036, Biology of Cancer and Infection, Grenoble, F-38054, France.,Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Commissariat à l'Energie Atomique (CEA), DSV/iRTSV, Grenoble, F-38054, France
| |
Collapse
|
6
|
Atallah I, Milet C, Henry M, Josserand V, Reyt E, Coll JL, Hurbin A, Righini CA. Near-infrared fluorescence imaging-guided surgery improves recurrence-free survival rate in novel orthotopic animal model of head and neck squamous cell carcinoma. Head Neck 2015; 38 Suppl 1:E246-55. [PMID: 25546527 DOI: 10.1002/hed.23980] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/18/2014] [Indexed: 11/07/2022] Open
Abstract
BACKGROUND Appropriate animal models are required to test novel therapeutics for head and neck squamous cell carcinoma (HNSCC) such as near-infrared (NIR) imaging-guided surgery. METHODS We developed an optimized animal model of orthotopic HNSCC (in female athymic NMRI (Naval Medical Research Institute) nude mice) with a prolonged survival time. Resection of the orthotopic tumors was performed 30 days after implantation with or without the aid of a miniaturized clinical grade NIR optical imaging device, after systemic administration of a fluorescent RGD-based probe that targets αv β3 integrin. RESULTS NIR optical imaging-guided surgery increased the recurrence-free survival rate by 50% through the detection of fluorescent cancer residues as small as 185 µm; these fragments could remain unidentified if resection was performed exclusively under unaided visual guidance. CONCLUSION NIR optical imaging-guided surgery showed an improved HNSCC tumor resection quality in our optimized orthotopic animal model. © 2015 Wiley Periodicals, Inc. Head Neck 38: E246-E255, 2016.
Collapse
Affiliation(s)
- Ihab Atallah
- INSERM U823, Grenoble Cedex, France.,Joseph Fourier University, Grenoble Cedex, France.,Department of Otolaryngology-Head and Neck Surgery, Grenoble University Hospital, Cedex, France
| | - Clément Milet
- INSERM U823, Grenoble Cedex, France.,Joseph Fourier University, Grenoble Cedex, France
| | - Maxime Henry
- INSERM U823, Grenoble Cedex, France.,Joseph Fourier University, Grenoble Cedex, France
| | - Véronique Josserand
- INSERM U823, Grenoble Cedex, France.,Joseph Fourier University, Grenoble Cedex, France
| | - Emile Reyt
- Joseph Fourier University, Grenoble Cedex, France.,Department of Otolaryngology-Head and Neck Surgery, Grenoble University Hospital, Cedex, France
| | - Jean-Luc Coll
- INSERM U823, Grenoble Cedex, France.,Joseph Fourier University, Grenoble Cedex, France
| | - Amandine Hurbin
- INSERM U823, Grenoble Cedex, France.,Joseph Fourier University, Grenoble Cedex, France
| | - Christian Adrien Righini
- INSERM U823, Grenoble Cedex, France.,Joseph Fourier University, Grenoble Cedex, France.,Department of Otolaryngology-Head and Neck Surgery, Grenoble University Hospital, Cedex, France
| |
Collapse
|
7
|
Liu J, Fan W, Liu M, Lin X, Wang Y, Wang F, Chen X, Cao F, Liang J. Spatial vascular volume fraction imaging for quantitative assessment of angiogenesis. Mol Imaging Biol 2015; 16:362-71. [PMID: 24158404 DOI: 10.1007/s11307-013-0694-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
PURPOSE The purpose of this study is to set up a quantitative imaging strategy for therapeutic angiogenesis and monitoring the spatial distribution and survival of the transplanted mesenchymal stem cells (MSCs) in vivo simultaneously. PROCEDURES Mouse adipose-derived MSCs (AD-MSCs) were isolated from firefly luciferase and enhanced green fluorescent protein positive transgenic mice, and implanted intramuscularly into hindlimbs of C57BL/6 mice. Serial spatial vascular volume fraction (SVVF) imaging was performed to quantitatively assess angiogenesis by calculating the spatially explicit vascular volume. The hybrid microcomputed tomography angiography/bioluminescence tomography (micro-CTA/BLT) was used to track the fate of AD-MSCs in vivo. Laser Doppler perfusion imaging (LDPI) was used to evaluate blood perfusion. Ex vivo conventional methods were performed to cross-validate the therapeutic angiogenesis. RESULTS There was a linear correlation relation between the cell number and Fluc/Fluc protein signal intensity in AD-MSCs via BLT. LDPI showed improved perfusion rate in mice treated with cytotherapy, compared to control mice. Furthermore, angiogenesis assessed by SVVF was 10.67 ± 0.41 %, 13.99 ± 0.28 %, and 23.50 ± 1.23 % on days 7, 14, and 28 post-transplantation of AD-MSCs, respectively. Vascular densities of the longitudinally monitored ischemic hindlimbs were significantly higher than those at early time points and controls, which was also confirmed by vascular corrosion casting, scanning electron microscopic imaging, and histological analysis. CONCLUSIONS Hybrid high-resolution micro-CTA/BLT enabled monitoring and quantitative assessment of cytotherapeutically induced angiogenesis in vivo.
Collapse
Affiliation(s)
- Junting Liu
- School of Life Science and Technology, Xidian University, P.O. Box 97, , No. 2 South Taibai Rd, Xi'an, 710071, China,
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Noninvasive and quantitative assessment of in vivo fetomaternal interface angiogenesis using RGD-based fluorescence. BIOMED RESEARCH INTERNATIONAL 2014; 2014:309082. [PMID: 25110672 PMCID: PMC4119748 DOI: 10.1155/2014/309082] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/03/2014] [Accepted: 05/27/2014] [Indexed: 11/17/2022]
Abstract
Angiogenesis is a key process for proper placental development and for the success of pregnancy. Although numerous in vitro methods have been developed for the assessment of this process, relatively few reliable in vivo methods are available to evaluate this activity throughout gestation. Here we report an in vivo technique that specifically measures placental neovascularization. The technique is based on the measurement of a fluorescent alpha v beta 3 (αvβ3) integrin-targeting molecule called Angiolone-Alexa-Fluor 700. The αvβ3 integrin is highly expressed by endothelial cells during the neovascularization and by trophoblast cells during their invasion of the maternal decidua. Angiolone was injected to gravid mice at 6.5 and 11.5 days post coitus (dpc). The fluorescence was analyzed one day later at 7.5 and 12.5 dpc, respectively. We demonstrated that (i) Angiolone targets αvβ3 protein in the placenta with a strong specificity, (ii) this technique is quantitative as the measurement was correlated to the increase of the placental size observed with increasing gestational age, and (iii) information on the outcome is possible, as abnormal placentation could be detected early on during gestation. In conclusion, we report the validation of a new noninvasive and quantitative method to assess the placental angiogenic activity, in vivo.
Collapse
|
9
|
Kéramidas M, de Fraipont F, Karageorgis A, Moisan A, Persoons V, Richard MJ, Coll JL, Rome C. The dual effect of mesenchymal stem cells on tumour growth and tumour angiogenesis. Stem Cell Res Ther 2013; 4:41. [PMID: 23628074 PMCID: PMC3706993 DOI: 10.1186/scrt195] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2012] [Accepted: 02/11/2013] [Indexed: 12/13/2022] Open
Abstract
INTRODUCTION Understanding the multiple biological functions played by human mesenchymal stem cells (hMSCs) as well as their development as therapeutics in regenerative medicine or in cancer treatment are major fields of research. Indeed, it has been established that hMSCs play a central role in the pathogenesis and progression of tumours, but their impact on tumour growth remains controversial. METHODS In this study, we investigated the influence of hMSCs on the growth of pre-established tumours. We engrafted nude mice with luciferase-positive mouse adenocarcinoma cells (TSA-Luc+) to obtain subcutaneous or lung tumours. When tumour presence was confirmed by non-invasive bioluminescence imaging, hMSCs were injected into the periphery of the SC tumours or delivered by systemic intravenous injection in mice bearing either SC tumours or lung metastasis. RESULTS Regardless of the tumour model and mode of hMSC injection, hMSC administration was always associated with decreased tumour growth due to an inhibition of tumour cell proliferation, likely resulting from deep modifications of the tumour angiogenesis. Indeed, we established that although hMSCs can induce the formation of new blood vessels in a non-tumoural cellulose sponge model in mice, they do not modify the overall amount of haemoglobin delivered into the SC tumours or lung metastasis. We observed that these tumour vessels were reduced in number but were longer. CONCLUSIONS Our results suggest that hMSCs injection decreased solid tumour growth in mice and modified tumour vasculature, which confirms hMSCs could be interesting to use for the treatment of pre-established tumours.
Collapse
|